Jamjoom Pharmaceuticals Factory Co. Board invites its shareholders to attend the Extraordinary General Assembly Meeting the ( First Meeting )

Element List	Explanation
Introduction	The Board of Directors of Jamjoom Pharmaceuticals Factory Company (the “Company”) is pleased to invite the esteemed shareholders to participate and cast their votes in the Extraordinary General Assembly Meeting (First Meeting). The meeting will be held on Tuesday 2/9/1445H corresponding to 12/3/2024G at (10:00) PM via modern technology means
City and Location of the General Assembly's Meeting	Company’s headquarters in Jeddah , via modern technology means (Online)
Hyperlink of the Meeting Location	Click Here
Date of the General Assembly's Meeting	2024-03-12 Corresponding to 1445-09-02
Time of the General Assembly’s Meeting	22:00
Methodology of Convening the General Assembly’s Meeting	Via modern technology means
Attendance Eligibility, Registration Eligibility, and Voting End	Shareholders who are registered in the issuers shareholders record at the Depositary Center by the end of the trade session prior to the general assembly meeting and in accordance with the laws and regulations. The right to register a name to attend the general assembly meeting ends at the time of convening the general assembly meeting. The attendees right to vote on the items of the assembly’s agenda ends upon the end of screening the votes by the Screening Committee.
Quorum for Convening the General Assembly's Meeting	The Extraordinary General Assembly Meeting shall not be held unless attended by shareholders owning at least one-half of Share Capital. If such quorum is not present, a second meeting shall be held after a lapse of an hour from the preceding meeting. The second meeting shall be deemed valid if attended by at least one-fourth of Share Capital.
General Assembly Meeting Agenda	1- Vote on the Board of Directors decision to appoint Mr. Georges P. Schorderet a member of the Board of Directors (independent member) starting from the date of his appointment on 15-12-1444H corresponding to 03-07-2023G to complete the Board Term until the end of the current session on June 18, 2025, succeeding the resigned Board Member Mr. Simon Goeller (independent member). (CV attached).

2- Vote on the amendment of the Remuneration Policy of the Members of the Board of Directors and its Committees and the Executive Management(attached).

3- Vote on amending Article (1) of the Company’s Bylaws which relates to the Company’s Incorporation (attached)

4- Voting on amending Article (3) of the Company’s Bylaws which relates to the Purposes of the Company (attached).

5- Vote on amending Article (8) of the Company’s Bylaws which relates to Shareholders’ Registry (attached).

6- Vote on amending Article (9) of the Company’s Bylaws which related to the Stock Trading (attached).

7- Vote on amending Article (10) of the Company’s Bylaws which relates to the Selling the Unpaid Shares (attached).

8- Vote on amending Article (13) of the Company’s Bylaws which relates to the Formation of the Board of Directors (attached).

9- Vote on amending Article (15) of the Company’s Bylaws which relates to the Expiry of the Board of Directors’ Term, Retirement of its Members, or Vacancy in Membership (attached).

10- Vote on amending Article (16) of the Company’s Bylaws which relates to the Board of Directors’ Powers (attached).

11- Vote on amending Article (17) of the Company’s Bylaws which relates to Remuneration of Board Members (attached).

12- Vote on amending Article (18) of the Company’s Bylaws which relates to the Powers of the Chairman, the Deputy Chairman, and the CEO or the Managing Director, and the Secretary (attached).

13- Vote on amending Article (20) of the Company’s Bylaws which relates to the Quorum and Board Decisions (attached).

14- Vote on amending Article (21) of the Company’s Bylaws which relates to the Board Deliberations (attached).

15- Vote on amending Article (23) of the Company’s Bylaws which relates to the Invitation for Assemblies (attached).

16- Vote on amending Article (27) of the Company’s Bylaws which relates to the Assemblies Decisions (attached).

17- Vote on deleting Article (30) from the Company’s Bylaws which relates to the Issuing General Assembly Decisions by Circulation (attached).

18- Vote on amending Article (36) of the Company’s Bylaws which relates to the Profit Entitlement and Interim Dividends (attached).

19- Vote on amending Article (38) of the Company’s Bylaws which relates to the Expiration of the Company (attached). Proxy Form The shareholder right in discussing the assembly agenda topics, asking questions, and exercising the voting right Shareholder are entitled to discuss matters listed in the agenda of the General Assembly and raise relevant questions to the Board members, noting that the voting is free of charge for all Shareholders via: http://tadawulaty.com.sa. Details of the electronic voting on the Assembly’s agenda Shareholders registered in Tadawulaty service will be able to vote electronically on the General Assembly’s agenda. Electronic voting will start on Saturday at 1:00 AM 28/8/1445 H corresponding to 9/3/2024 G, and will last until the end of the General assembly time.: Method of Communication in Case of Any Enquiries In case of any inquiries and shareholders questions on this meeting’s agenda items can be received through the Investors Relations Department’s email address at Email: IR@jamjoompharma.com

Shareholders can also

call Tel: +966 12 614 0099 ext. 3313

Mobile: +966 50 985 3577 Attached Documents

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.